Chemo-Immunotherapy: A New Trend in Cancer Treatment
Chemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under defined conditions, may stimulate antitumor immunity and potentiate...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/11/2912 |
| _version_ | 1797597835552620544 |
|---|---|
| author | Christian Sordo-Bahamonde Seila Lorenzo-Herrero Ana P. Gonzalez-Rodriguez Alejandra Martínez-Pérez Juan P. Rodrigo Juana M. García-Pedrero Segundo Gonzalez |
| author_facet | Christian Sordo-Bahamonde Seila Lorenzo-Herrero Ana P. Gonzalez-Rodriguez Alejandra Martínez-Pérez Juan P. Rodrigo Juana M. García-Pedrero Segundo Gonzalez |
| author_sort | Christian Sordo-Bahamonde |
| collection | DOAJ |
| description | Chemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under defined conditions, may stimulate antitumor immunity and potentiate immune checkpoint inhibitor (ICI)-based therapy. Its effectiveness has been highlighted by recent regulatory approvals of various combinations of chemotherapy with ICIs in several tumors, particularly in some difficult-to-treat cancers. This review discusses the immune modulatory properties of chemotherapy and how they may be harnessed to develop novel chemo-immunotherapy combinations. It also highlights the key determinants of the success of chemo-immunotherapy and provides an overview of the combined chemo-immunotherapies that have been clinically approved. |
| first_indexed | 2024-03-11T03:11:05Z |
| format | Article |
| id | doaj.art-f606a232901c46e397a6579e1a0c110c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T03:11:05Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f606a232901c46e397a6579e1a0c110c2023-11-18T07:38:15ZengMDPI AGCancers2072-66942023-05-011511291210.3390/cancers15112912Chemo-Immunotherapy: A New Trend in Cancer TreatmentChristian Sordo-Bahamonde0Seila Lorenzo-Herrero1Ana P. Gonzalez-Rodriguez2Alejandra Martínez-Pérez3Juan P. Rodrigo4Juana M. García-Pedrero5Segundo Gonzalez6Department of Functional Biology, Immunology, Universidad de Oviedo, 33006 Oviedo, SpainDepartment of Functional Biology, Immunology, Universidad de Oviedo, 33006 Oviedo, SpainInstituto Universitario de Oncología del Principado de Asturias (IUOPA), 33006 Oviedo, SpainDepartment of Functional Biology, Immunology, Universidad de Oviedo, 33006 Oviedo, SpainInstituto Universitario de Oncología del Principado de Asturias (IUOPA), 33006 Oviedo, SpainInstituto Universitario de Oncología del Principado de Asturias (IUOPA), 33006 Oviedo, SpainDepartment of Functional Biology, Immunology, Universidad de Oviedo, 33006 Oviedo, SpainChemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under defined conditions, may stimulate antitumor immunity and potentiate immune checkpoint inhibitor (ICI)-based therapy. Its effectiveness has been highlighted by recent regulatory approvals of various combinations of chemotherapy with ICIs in several tumors, particularly in some difficult-to-treat cancers. This review discusses the immune modulatory properties of chemotherapy and how they may be harnessed to develop novel chemo-immunotherapy combinations. It also highlights the key determinants of the success of chemo-immunotherapy and provides an overview of the combined chemo-immunotherapies that have been clinically approved.https://www.mdpi.com/2072-6694/15/11/2912immunotherapychemotherapyimmune checkpointsPD-1T cellNK cell |
| spellingShingle | Christian Sordo-Bahamonde Seila Lorenzo-Herrero Ana P. Gonzalez-Rodriguez Alejandra Martínez-Pérez Juan P. Rodrigo Juana M. García-Pedrero Segundo Gonzalez Chemo-Immunotherapy: A New Trend in Cancer Treatment Cancers immunotherapy chemotherapy immune checkpoints PD-1 T cell NK cell |
| title | Chemo-Immunotherapy: A New Trend in Cancer Treatment |
| title_full | Chemo-Immunotherapy: A New Trend in Cancer Treatment |
| title_fullStr | Chemo-Immunotherapy: A New Trend in Cancer Treatment |
| title_full_unstemmed | Chemo-Immunotherapy: A New Trend in Cancer Treatment |
| title_short | Chemo-Immunotherapy: A New Trend in Cancer Treatment |
| title_sort | chemo immunotherapy a new trend in cancer treatment |
| topic | immunotherapy chemotherapy immune checkpoints PD-1 T cell NK cell |
| url | https://www.mdpi.com/2072-6694/15/11/2912 |
| work_keys_str_mv | AT christiansordobahamonde chemoimmunotherapyanewtrendincancertreatment AT seilalorenzoherrero chemoimmunotherapyanewtrendincancertreatment AT anapgonzalezrodriguez chemoimmunotherapyanewtrendincancertreatment AT alejandramartinezperez chemoimmunotherapyanewtrendincancertreatment AT juanprodrigo chemoimmunotherapyanewtrendincancertreatment AT juanamgarciapedrero chemoimmunotherapyanewtrendincancertreatment AT segundogonzalez chemoimmunotherapyanewtrendincancertreatment |